Zelik Bocknek is a retired business owner and lives in Toronto, Canada. Zelik is living with early Alzheimer’s disease and is ...
Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be ...
Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has ...
Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy ...
A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...
Medicare could save millions of dollars every year by changing the way they package Alzheimer's medication.
European regulators have for the fourth time issued a negative opinion on PTC's Translarna. Elsewhere, Amylyx read out data ...
About 6% of Leqembi (lecanemab) is discarded because patients are frequently prescribed doses lower than the size of the drug’s single-use vials. This waste costs Medicare about $1,600 a patient ...
Neurophet to host Symposium featuring renowned expert in Alzheimer's disease treatment from the U.S.
Neurophet has specialized in developing solutions for diagnosis support, treatment guides, and treatment devices targeting ...
Biogen (BIIB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit Bansal ...
About 6% of Leqembi is thrown away because there’s leftover drug after a dose is drawn to match a person’s weight Adding a 75-milligram vial could reduce waste by 74% and save Medicare as much ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback